Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05738434 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 21, 2024 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 2024 to Sep 1, 2025
    • Study completion date: Nov 2026 to Mar 1, 2027
    v3
  2. Start date changed from estimate of Feb 2023 to Mar 2, 2023
    • Eligibility criteria revised
    • Secondary endpoints: details revised at 1 of 6 entries
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the efficacy and safety of patients with advanced esophageal squamous cell carcinoma treated with camrelizumab combined with Apatinib mesylate plus short-course chemotherapy versus standard chemotherapy in first line
Trial Details
NCT Number NCT05738434
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions
(from sponsor)		 Esophageal Cancer by AJCC V8 Stage
Enrollment 188 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov